novidades científicas Novo

16:13 European Cardiovascular Disease Statistics 2017
10:47 CETP inhibitor meets primary endpoint in CV outcome study
9:54 Arrhythmias and devices
14:31 Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
14:18 Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Cardiac amyloidosis. What the clinicians should know – Franz Duca

2 Agosto 2019

Resumo da Apresentação

Apresentação

Synergy of dual pathway inhibition in chronic cardiovascular disease - Robert Welsh

2 Agosto 2019
0

Sudden death in patients with heart failure. The role of sacubitril/valsartan - Carlos de Diego

2 Agosto 2019
0

-->